VICKS COLD FLU & COUGH ALL IN ONE is a brand name for Guaifenesin. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: Short term symptomatic relief of mild to moderate pain, fever, nasal congestion with an expectorant effect on chesty cough, associated with colds, chills and influenza in adults and adolescents aged 12 years and older. Vicks Cold, Flu & Cough All In One should only be used if all symptoms (pain and/or fever, nasal…
Verbatim from this product's MHRA label. Tap a section to expand.
Posology Adults, the elderly and adolescents aged 12 years and over:
The recommended single dose is one sachet which can be taken up to four times a day as required with the interval of at least four hours between doses. The maximum daily dose of four sachets must not be exceeded in any 24-hour period.
3). 3). Seek medical advice if symptoms persist for more than 3 days. Paediatric population Vicks Cold, Flu & Cough All In One is not intended for children under 12 years of age. Method of administration 2 Business UseBusiness Use Dissolve the contents of one sachet in a standard mug of hot, but not boiling, water (approx.
250 ml). Allow to cool to a drinkable temperature.
g. thrombocytopenia, agranulocytosis, haemolytic anaemia, neutropenia, leucopenia, pancytopenia has been reported with paracetamol, but these were not necessarily causally related. Immune system disorders Rare: allergic or hypersensitivity reactions with both phenylephrine and paracetamol, including anaphylaxis.
Very rare: hypersensitivity reactions such as oedema of the face, lips, tongue or throat or difficulty breathing have been reported with guaifenesin. Nervous system disorders As with other sympathomimetic amines insomnia, nervousness, tremor, anxiety, restlessness, confusion, irritability, dizziness and headache may rarely occur with phenylephrine.
Headache and dizziness are also known to occur rarely with Guaifenesin. 6 Business UseBusiness Use Cardiac disorders Phenylephrine may rarely be associated with tachycardia and palpitations. Vascular disorders High blood pressure may occur rarely with phenylephrine.
Gastrointestinal disorders Rare: gastrointestinal discomfort, abdominal pain, nausea, vomiting, diarrhoea, and anorexia. g. increase in hepatic transaminases, jaundice).
Skin and subcutaneous disorders Rare:
Hypersensitivity reactions including skin rash and urticaria. Very rare cases of serious skin reactions have been reported with paracetamol. Renal and urinary disorders Interstitial nephritis has been reported incidentally after prolonged use of high doses of paracetamol.
Metabolism and nutrition disorders Frequency not known:
High anion gap metabolic acidosis. 4). Pyroglutamic acidosis may occur as a consequence of low glutathione levels in these patients.
Respiratory, thoracic and mediastinal disorders Rare:
Long term use of the product is not recommended. Patients should be advised not to take with other paracetamol-containing products or other products containing the same active ingredients as this preparation, in order to avoid the risk of an overdose.
Exceeding the recommended dose of paracetamol may result in severe liver impairment. Patients should also be advised not to take other cough, cold or decongestant products concurrently, or alcohol. e. orally and topically (nasal, aural and eye preparations).
The hazards of overdose are greater in those with - non-cirrhotic alcoholic liver disease. - chronic alcohol abuse Use with caution in patients with prostatic hypertrophy as they may be susceptible to urinary retention. Use with caution in patients with Raynaud’s phenomenon.
Care is advised in the administration of guaifenesin to patients with a persistent or chronic cough such as occurs with smoking, asthma, chronic bronchitis, emphysema or cough with excessive mucus to avoid prolonged self-medication and masking the symptoms requiring more complex treatment.
Precaution is needed when paracetamol is administered in patients with severe haemolytic anaemia, glucose-6-dehydrogenase deficit, dehydrated patients, and patients with chronic malnutrition disorders. , chronic alcoholism) who 3 Business UseBusiness Use were treated with paracetamol at therapeutic dose for a prolonged period or a combination of paracetamol and flucloxacillin.
If HAGMA due to pyroglutamic acidosis is suspected, prompt discontinuation of paracetamol and close monitoring is recommended. The measurement of urinary 5-oxoproline may be useful to identify pyroglutamic acidosis as underlying cause of HAGMA in patients with multiple risk factors.
Excipients with known effect Contains sucrose. Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrose-isomaltase insufficiency should not take this medicine. 85% of the WHO recommended maximum daily intake of 2 g sodium for an adult.
1. • Hepatic or severe renal impairment • Hypertension • Hyperthyroidism, • Diabetes, • Heart disease, • Narrow-angle glaucoma • Porphyria • Use in patients taking tricyclic antidepressants • Use in patients who are currently taking or have taken monoamine oxidase inhibitors (MAOIs) within the last 2 weeks • Use in patients taking beta-blocking drugs • Use in patients who are currently taking other sympathomimetic drugs
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Guaifenesin in United Kingdom.
Know a brand we are missing in United Kingdom? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
Bronchospasm. Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.
uk/yellowcard, or search for MHRA Yellow Card in the Google Play or Apple App Store.
Contains aspartame (E951) a source of phenylalanine. May be harmful for people with phenylketonuria.